MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/520/0.01/20.09.24 Stock MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/520/0.01/20.09.24
Add to a list
To use this feature you must be a member
Log inSign up

MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/520/0.01/20.09.24 Stock

Warrant

DE000ME4N3M1

Market Closed - Börse Stuttgart 14:07:53 2024-07-05 EDT
0.098 EUR +6.52% Intraday chart for MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/520/0.01/20.09.24
Current month-11.71%
1 month-42.01%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart VERTEX PHARMACEUTICALS INCORPORATED
Chart MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/520/0.01/20.09.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis MT
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy DJ
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis BU
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment for Cystic Fibrosis CI
More news

Quotes 5-day view

Date Price Change
24-07-05 0.098 +6.52%
24-07-04 0.092 +1.10%
24-07-03 0.091 -9.00%
24-07-02 0.1 0.00%
24-07-01 0.1 -9.91%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 02:07 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying VERTEX PHARMACEUTICALS INCORPORATED
Issuer Morgan Stanley
WKN ME4N3M
ISINDE000ME4N3M1
Date issued 2023-12-05
Strike 520 $
Maturity 2024-09-20 (76 Days)
Parity 100 : 1
Emission price 0.08 €
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.207 €
Lowest since issue 0.046 €
Delta0.3x
Omega 12.63
Premium11.95x
Gearing42.49x
Moneyness 0.9125
Difference Strike 45.52 $
Difference Strike %+8.75%
Spread 0.01 €
Spread %9.26%
Theoretical value 0.1030
Implied Volatility 29.20 %
Total Loss Probability 74.75 %
Intrinsic value 0.000000
Present value 0.1030
Break even 531.17 €
Theta-0.01x
Vega0.01x
Rho0x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474.6 USD
Average target price
468.3 USD
Spread / Average Target
-1.33%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant